vs
Amneal Pharmaceuticals, Inc.（AMRX）与Dayforce（DAY）财务数据对比。点击上方公司名可切换其他公司
Amneal Pharmaceuticals, Inc.的季度营收约是Dayforce的1.5倍（$722.5M vs $481.6M），Amneal Pharmaceuticals, Inc.净利率更高（10.8% vs -40.9%，领先51.7%），Dayforce同比增速更快（9.5% vs 3.9%），过去两年Dayforce的营收复合增速更高（9.8% vs 1.5%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Dayforce前身为知名人力资源服务商Ceridian，是一家总部位于美国的人力资源软件及服务企业，面向各行业不同规模的客户提供覆盖薪酬核算、人员管理、考勤等多场景的HR SaaS产品及配套专业服务，助力企业提升人力资源运营效率。
AMRX vs DAY — 直观对比
营收规模更大
AMRX
是对方的1.5倍
$481.6M
营收增速更快
DAY
高出5.6%
3.9%
净利率更高
AMRX
高出51.7%
-40.9%
两年增速更快
DAY
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $481.6M |
| 净利润 | $78.0M | $-196.8M |
| 毛利率 | 44.3% | — |
| 营业利润率 | 19.6% | 6.3% |
| 净利率 | 10.8% | -40.9% |
| 营收同比 | 3.9% | 9.5% |
| 净利润同比 | 410.5% | -9940.0% |
| 每股收益（稀释后） | $0.19 | $-1.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXDAY
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | — | ||
| Q3 25 | $784.5M | $481.6M | ||
| Q2 25 | $724.5M | $464.7M | ||
| Q1 25 | $695.4M | $481.8M | ||
| Q4 24 | $730.5M | $465.2M | ||
| Q3 24 | $702.5M | $440.0M | ||
| Q2 24 | $701.8M | $423.3M |
净利润AMRXDAY
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | — | ||
| Q3 25 | $2.4M | $-196.8M | ||
| Q2 25 | $22.4M | $21.3M | ||
| Q1 25 | $12.2M | $14.9M | ||
| Q4 24 | $-31.1M | $10.8M | ||
| Q3 24 | $-156.0K | $2.0M | ||
| Q2 24 | $6.0M | $-1.8M |
毛利率AMRXDAY
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | 47.0% | ||
| Q3 24 | 38.4% | 45.8% | ||
| Q2 24 | 35.6% | 44.1% |
营业利润率AMRXDAY
| Q1 26 | 19.6% | — | ||
| Q4 25 | 13.8% | — | ||
| Q3 25 | 9.0% | 6.3% | ||
| Q2 25 | 15.4% | 9.1% | ||
| Q1 25 | 14.4% | 6.4% | ||
| Q4 24 | 10.4% | 6.1% | ||
| Q3 24 | 12.6% | 4.7% | ||
| Q2 24 | 13.6% | 3.3% |
净利率AMRXDAY
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | — | ||
| Q3 25 | 0.3% | -40.9% | ||
| Q2 25 | 3.1% | 4.6% | ||
| Q1 25 | 1.8% | 3.1% | ||
| Q4 24 | -4.3% | 2.3% | ||
| Q3 24 | -0.0% | 0.5% | ||
| Q2 24 | 0.9% | -0.4% |
每股收益（稀释后）AMRXDAY
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | — | ||
| Q3 25 | $0.01 | $-1.23 | ||
| Q2 25 | $0.07 | $0.13 | ||
| Q1 25 | $0.04 | $0.09 | ||
| Q4 24 | $-0.10 | $0.07 | ||
| Q3 24 | $0.00 | $0.01 | ||
| Q2 24 | $0.02 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $197.7M | $627.6M |
| 总债务越低越好 | — | $631.1M |
| 股东权益账面价值 | — | $2.7B |
| 总资产 | $3.5B | $8.7B |
| 负债/权益比越低杠杆越低 | — | 0.23× |
8季度趋势，按日历期对齐
现金及短期投资AMRXDAY
| Q1 26 | $197.7M | — | ||
| Q4 25 | $282.0M | — | ||
| Q3 25 | $201.2M | $627.6M | ||
| Q2 25 | $71.5M | $625.2M | ||
| Q1 25 | $59.2M | $557.3M | ||
| Q4 24 | $110.6M | $579.7M | ||
| Q3 24 | $74.0M | $494.1M | ||
| Q2 24 | $43.8M | $465.4M |
总债务AMRXDAY
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | $631.1M | ||
| Q2 25 | $2.2B | $631.8M | ||
| Q1 25 | $2.2B | $632.4M | ||
| Q4 24 | $2.4B | $1.2B | ||
| Q3 24 | $2.4B | $1.2B | ||
| Q2 24 | $2.4B | $1.2B |
股东权益AMRXDAY
| Q1 26 | — | — | ||
| Q4 25 | $-70.8M | — | ||
| Q3 25 | $-109.5M | $2.7B | ||
| Q2 25 | $-112.1M | $2.7B | ||
| Q1 25 | $-131.7M | $2.6B | ||
| Q4 24 | $-109.3M | $2.5B | ||
| Q3 24 | $-93.4M | $2.6B | ||
| Q2 24 | $-57.5M | $2.5B |
总资产AMRXDAY
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.7B | — | ||
| Q3 25 | $3.6B | $8.7B | ||
| Q2 25 | $3.4B | $8.5B | ||
| Q1 25 | $3.4B | $9.5B | ||
| Q4 24 | $3.5B | $9.1B | ||
| Q3 24 | $3.5B | $8.1B | ||
| Q2 24 | $3.5B | $9.0B |
负债/权益比AMRXDAY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.47× | ||
| Q2 24 | — | 0.49× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $31.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AMRXDAY
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | — | ||
| Q3 25 | $118.5M | $31.2M | ||
| Q2 25 | $83.8M | $112.7M | ||
| Q1 25 | $7.4M | $49.6M | ||
| Q4 24 | $118.1M | $81.0M | ||
| Q3 24 | $141.8M | $91.8M | ||
| Q2 24 | $39.7M | $99.2M |
自由现金流AMRXDAY
| Q1 26 | — | — | ||
| Q4 25 | $108.5M | — | ||
| Q3 25 | $106.2M | — | ||
| Q2 25 | $61.0M | — | ||
| Q1 25 | $-5.8M | — | ||
| Q4 24 | $102.9M | — | ||
| Q3 24 | $124.8M | — | ||
| Q2 24 | $29.0M | — |
自由现金流率AMRXDAY
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | — | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 17.8% | — | ||
| Q2 24 | 4.1% | — |
资本支出强度AMRXDAY
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.5% | — |
现金转化率AMRXDAY
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | 5.29× | ||
| Q1 25 | 0.61× | 3.33× | ||
| Q4 24 | — | 7.50× | ||
| Q3 24 | — | 45.90× | ||
| Q2 24 | 6.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
暂无分部数据
DAY
| Dayforce Recurring | $333.0M | 69% |
| Cloud And Bureau Professional Services And Other | $78.5M | 16% |
| Float | $42.2M | 9% |
| Powerpay Recurring | $19.7M | 4% |
| Other Recurring | $8.2M | 2% |
